Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

164. Linagliptin-metformin (Jentadueto - Boehringer Ingelheim (Canada) Ltd.) indication: type 2 diabetes mellitus

Linagliptin-metformin (Jentadueto - Boehringer Ingelheim (Canada) Ltd.) indication: type 2 diabetes mellitus Linagliptin-metformin (Jentadueto - Boehringer Ingelheim (Canada) Ltd.) indication: type 2 diabetes mellitus Linagliptin-metformin (Jentadueto - Boehringer Ingelheim (Canada) Ltd.) indication: type 2 diabetes mellitus CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation CADTH. Linagliptin-metformin (Jentadueto - Boehringer Ingelheim (Canada) Ltd.) indication: type 2 diabetes mellitus. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2013 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that linagliptin/metformin (Jentadueto) be listed for patients if the following clinical criterion is met: Patients for whom insulin is not an option and who are already

Health Technology Assessment (HTA) Database.2013

168. Systematic review with meta-analysis: Metformin may not reduce cardiovascular risk or all-cause mortality

Systematic review with meta-analysis: Metformin may not reduce cardiovascular risk or all-cause mortality Metformin may not reduce cardiovascular risk or all-cause mortality | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main (...) menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metformin may not reduce cardiovascular risk or all-cause mortality Article Text Online articles Systematic review with meta-analysis Metformin may not reduce cardiovascular risk or all-cause mortality Matteo Monami Correspondence to : Matteo Monami Department of Cardiovascular Medicine, Section of Diabetes, Cardiovascular

Evidence-Based Medicine (Requires free registration)2013

169. Randomised controlled trial: Should metformin be preferred over insulin therapy in the management of gestational diabetes (GDM)?

Randomised controlled trial: Should metformin be preferred over insulin therapy in the management of gestational diabetes (GDM)? Should metformin be preferred over insulin therapy in the management of gestational diabetes (GDM)? | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Should metformin be preferred over insulin therapy in the management of gestational diabetes (GDM)? Article Text Therapeutics Randomised controlled trial Should metformin be preferred over insulin therapy in the management of gestational diabetes (GDM)? Shannon D Sullivan

Evidence-Based Medicine (Requires free registration)2013

170. Clinical Use of Metformin in Non-Diabetic, Obese, At-Risk Adolescents: A Systematic Review

Clinical Use of Metformin in Non-Diabetic, Obese, At-Risk Adolescents: A Systematic Review "Clinical Use of Metformin in Non-Diabetic, Obese, At-Risk Adolescents:" by Regan R. Brown < > > > > > Title Author Date of Award Summer 8-10-2013 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Sage-Davis Risen, PA-C Second Advisor Annjanette Sommers, PA-C Rights . Abstract Background : Type 2 diabetes (T2D) is a disease effecting people of every (...) of the disease. The purpose of this study is to explore the preventative potential of metformin in obese, non-diabetic adolescents at-risk for the development of T2D. Methods : An exhaustive search of available medical literature was conducted using Medline-OVID, CINAHL, and Google Scholar using the key words: adolescents, metformin, diabetes – prevention and control, obesity, and diabetic risk factors. Articles with primary data evaluating the use of metformin in obese, non-diabetic adolescents were

Pacific University EBM Capstone Project2013

171. The Impact of a Concurrent Exercise Program With Metformin and Rosiglitazone on Glycemic Control

The Impact of a Concurrent Exercise Program With Metformin and Rosiglitazone on Glycemic Control "The Impact of a Concurrent Exercise Program With Metformin and Rosigli" by Robert E. Horner < > > > > > Title Author Date of Award Summer 8-10-2013 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Type 2 diabetes mellitus is a growing disorder throughout the world. Two of the major treatment modalities are used concurrently (...) to fight inadequate glycemic control is exercise and diabetic medications. Metformin and rosiglitazone are diabetic medications known to improve glycemic control. Metformin lowers exercise capacity in diabetics while rosiglitazone improves exercise capacity. Given the impact of metformin and rosiglitazone on exercise capacity, the overall improvements in glycemic control, when used with a concurrent exercise program, needs to be examined. Method: An exhaustive search of available medical literature

Pacific University EBM Capstone Project2013

174. Kazano (alogliptin and metformin hydrochloride)

Kazano (alogliptin and metformin hydrochloride) Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Kazano (alogliptin and metformin hydrochloride) Tablets Company: Takeda Pharmaceuticals U.S.A., Inc. Application No.: 203414 Approval Date: 1/25/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2013

175. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus 22369287 2012 07 03 2012 11 05 2013 11 21 1463-1326 14 8 2012 Aug Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. 737-44 10.1111/j.1463-1326.2012.01593.x To investigate the efficacy and tolerability of vildagliptin as add-on therapy to metformin (...) in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin. This was a 24-week, randomized, double-blind, placebo-controlled study. Patients with T2DM (N = 438) with haemoglobin A1c (HbA1c) of 7.0-10.0% and fasting plasma glucose (FPG) <15 mmol/l (<270 mg/dl) were randomized (1 : 1 : 1) to vildagliptin 50 mg bid, vildagliptin 50 mg qd or placebo in addition to metformin. The treatment groups were well balanced at baseline [mean HbA1c, 8.0%, FPG, 8.8 mmol/l (158 mg/dl

EvidenceUpdates2013

176. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. 23850055 2013 09 16 2013 09 26 2015 11 19 1474-547X 382 9896 2013 Sep 14 Lancet (London, England) Lancet Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from (...) a randomised, double-blind, phase 3 non-inferiority trial. 941-50 10.1016/S0140-6736(13)60683-2 S0140-6736(13)60683-2 Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the efficacy and safety of canagliflozin, an SGLT2 inhibitor, with glimepiride in patients with type 2 diabetes inadequately controlled with metformin. We undertook this 52 week, randomised, double-blind, active-controlled, phase 3 non

Lancet2013

177. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials

Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel JP, Kassai B, Moreau A, Gueyffier F, Cornu C CRD summary This meta (...) -analysis found no evidence of benefit from metformin versus control therapy for type 2 diabetes, for all-cause or cardiovascular mortality and cardiovascular events; it could increase or decrease the death rate. The authors’ conclusions should be treated with caution, as they recommended, due to the limited evidence. Authors' objectives To evaluate the cardiovascular mortality and morbidity and all-cause mortality with metformin for type 2 diabetes. Searching MEDLINE, EMBASE and Cochrane Database

DARE.2012

178. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with Type 2 diabetes experiencing inadequate glycaemic control on metformin and sitaglipti

A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with Type 2 diabetes experiencing inadequate glycaemic control on metformin and sitaglipti 22375612 2012 10 08 2013 02 20 2015 11 19 1464-5491 29 11 2012 Nov Diabetic medicine : a journal of the British Diabetic Association Diabet. Med. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin (...) or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin. e417-24 10.1111/j.1464-5491.2012.03624.x To test the hypothesis that glycaemic control achieved when switching sitagliptin to exenatide twice daily plus metformin is non-inferior to adding exenatide twice daily to sitagliptin and metformin. Patients with Type 2 diabetes inadequately controlled with sitagliptin plus metformin were randomly assigned

EvidenceUpdates2012

179. Long versus short course treatment with metformin and clomiphene citrate for ovulation induction in women with PCOS.

Long versus short course treatment with metformin and clomiphene citrate for ovulation induction in women with PCOS. BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy among reproductive-aged women. Apart from infertility, women with PCOS often have other endocrine disorders, including insulin resistance, hyperinsulinaemia and hyperandrogenism. Metformin,combined with clomiphene citrate (CC), has been shown to be more effective in ovulation induction when compared (...) with clomiphene citrate alone. The optimal duration for metformin pretreatment before initiation of clomiphene citrate, however, is unknown. OBJECTIVES: To determine the effectiveness of short-course (less than four weeks) metformin plus CC versus long-course (four weeks or more) metformin plus CC with regard to ovulation and achievement of pregnancy in infertile women with PCOS. SEARCH METHODS: We searched the Cochrane Menstrual Disorders and Subfertility Group Trials Register, the Cochrane Central Register

Cochrane2012

180. Review: DPP-4 inhibitors are less effective than metformin for reducing HbA1c in type 2 diabetes.

Review: DPP-4 inhibitors are less effective than metformin for reducing HbA1c in type 2 diabetes. ACP Journal Club. Review: DPP-4 inhibitors are less effective than metformin for reducing HbA(1c) in type 2 diabetes. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography (...) Citation manager Format Create File 1 selected item: 22801704 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Jul 17;157(2):JC2-13. doi: 10.7326/0003-4819-157-2-201207170-02013. ACP Journal Club. Review: DPP-4 inhibitors are less effective than metformin for reducing HbA(1c) in type 2 diabetes. . Comment on [BMJ. 2012] PMID

Annals of Internal Medicine2012